Heteroaryl imidazolone derivatives as JAK inhibitors
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ALMIRALL
- Publication Date
- 2013-02-13
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
Background technique
[0001] Cytokines play a pivotal role in regulating many aspects of immunity and inflammation, which can range from the development and differentiation of immune cells to the suppression of immune responses. Type I and type II cytokine receptors lack intrinsic enzymatic activity to mediate signal transduction and, therefore, require association with tyrosine kinases for this purpose. The JAK family of kinases includes four distinct members, namely JAK1, JAK2, JAK3 and TYK2, which control signal transduction by binding type I and type II cytokine receptors (Murray PJ, (2007). The JAK-STAT signaling pathway: input and output integration. J Immunol, 178:2623). Each JAK kinase is selective for a particular cytokine receptor. In this regard, JAK-deficient cell lines and mice have demonstrated the following important roles for each JAK protein in the receptor pathway: JAK1 binds type II cytokine receptors (IFN and IL-10 families), which share the gp130 chain (...